Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

bioresorbable stents
Feature | Dave Fornell
Ongoing clinical trials of bioresorbable stents continue to show positive data for the devices, which are widely ...
Home December 31, 2014
Home
News

December 31, 2014 — Reva Medical initiated patient enrollment with its Fantom bioresorbable drug-eluting scaffold. The ...

Home December 31, 2014
Home
News

December 10, 2014 — In the first successful United States trial of a bioabsorbable polymer stent, the Boston Scientific ...

Home December 10, 2014
Home
News

Nov. 14, 2014 — Micell Technologies Inc. announced commercialization plans for its MiStent Sirolimus Eluting Absorbable ...

Home November 14, 2014
Home
News

By Dave Fornell, editor of DAIC Magazine

The key take away messages from the 26th annual Transcatheter Cardiovascular ...

Home November 03, 2014
Home
Feature

October 8, 2014 — Abbott announced the start of the ABSORB IV clinical trial, which will test whether the Absorb bioreso ...

Home October 08, 2014
Home
News

October 7,2014 — Amaranth Medical announced patient enrollment in multiple centers in Colombia, South America in MEND-II ...

Home October 07, 2014
Home
Blog

By Dave Fornell, editor of DAIC Magazine


The key take away messages from the 26th annual Transcatheter Cardiovascular ...

Home September 26, 2014
Home
News
September 26, 2014 — A first-of-its kind study comparing the safety and efficacy of biodegradable polymer sirolimus ...
Home September 26, 2014
Home
News

September 24, 2014 — A new study that compares the use of an everolimus-eluting bioresorbable vascular scaffold (BVS) ...

Home September 24, 2014
Home
ABSORB II Study DES Xience Abbot Vascular
Feature

September 24, 2014 — Abbott announced positive one-year clinical results from ABSORB II, the world's first prospective ...

Home September 24, 2014
Home
Videos | Stents Bioresorbable

DAIC Editor, Dave Fornell, interviews  Jim Hermiller, M.D., FACC, director of interventional cardiology, St. Vincent ...

Home September 24, 2014
Home
bioresorbable stents, dissolving stents, Absorb stent, BVS
Feature | Stents Bioresorbable | Dave Fornell
Home September 03, 2014
Home
News

July 10, 2014 — 480 Biomedical announced it has been awarded Phase II funding from the National Heart, Lung, and Blood ...

Home July 10, 2014
Home
Elixir Medical Corp. DESolve 100 CE mark
Feature

May 13, 2014 — Elixir Medical Corp. received European CE mark approval for its DESolve 100 Novolimus-eluting Bioresorbab ...

Home May 13, 2014
Home
Subscribe Now